Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Open Access
- 23 May 2005
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (10) , 1154-1160
- https://doi.org/10.1001/archinte.165.10.1154
Abstract
Research from JAMA Internal Medicine — Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic SyndromeThis publication has 28 references indexed in Scilit:
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- What to Do About the Metabolic Syndrome?Archives of internal medicine (1960), 2003
- Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)Cardiovascular Diabetology, 2003
- Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination SurveyObstetrical & Gynecological Survey, 2002
- Medical significance of peroxisome proliferator-activated receptorsThe Lancet, 1999
- Clustering of Metabolic Factors and Coronary Heart DiseaseArchives of internal medicine (1960), 1999
- Insulin resistance: the fundamental trigger of type 2 diabetesDiabetes, Obesity and Metabolism, 1999
- Hypertension and Associated Metabolic Abnormalities — The Role of Insulin Resistance and the Sympathoadrenal SystemNew England Journal of Medicine, 1996
- The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertensionArchives of internal medicine (1960), 1989
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988